Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
30 stopped studies mapped to High-Grade Glioma, NOS and descendants · 93% state a reason
Over the 30 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03952598 | Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of… | Phase 2 | suspended | May 16, 2019 | National Cancer Institute (NCI) | Study on hold pending possible updates with the team. | Other (stated, no rule matched) |
| NCT04559685 | Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma | Early Phase 1 | terminated | Sep 23, 2020 | Nader Sanai | Study terminated due to unavailability of the investigational product required to continue the… | Other (stated, no rule matched) |
| NCT05773326 | Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG | Early Phase 1 | terminated | Mar 17, 2023 | Nader Sanai | Study terminated due to unavailability of the investigational product required to continue the… | Other (stated, no rule matched) |
| NCT03334305 | Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas(ACTION) | Phase 1 | terminated | Nov 7, 2017 | University of Florida | due to lack of accrual/feasibility to complete accrual due to competing trials | Enrollment / accrual |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | Phase 2 | withdrawn | Jul 23, 2020 | Pediatric Brain Tumor Consortium | The PBTC lost federal funding and will cease operations in March 2026.PBTC-061 was permanently… | Enrollment / accrual |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma(NeoGlio) | Phase 2 | terminated | Dec 24, 2019 | Geisinger Clinic | Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25… | Other (stated, no rule matched) |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High… | Phase 1 | withdrawn | Jul 15, 2024 | University of Nebraska | PI leaving institution. | Other (stated, no rule matched) |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System… | Phase 1 / Phase 2 | terminated | Oct 1, 2018 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients… | Phase 1 / Phase 2 | terminated | Feb 21, 2023 | Dawonmedax Co., Ltd. | The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial… | Other (stated, no rule matched) |
| NCT04552756 | Seizures During Radiotherapy for High-grade Gliomas(SURF-ROGG) | N/A | terminated | Sep 17, 2020 | University Hospital Schleswig-Holstein | The study was terminated after enrollment of 23 patients, since the required number of 10 events… | Enrollment / accrual |
| NCT06463184 | Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma… | Phase 1 | withdrawn | Jun 17, 2024 | H. Lee Moffitt Cancer Center and Research Institute | funding issues | Funding |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused… | Phase 1 | withdrawn | Oct 19, 2021 | WPD Pharmaceuticals Sp. z o.o. | Business decision | Sponsor / business decision |
| NCT05394558 | AsiDNA Children, Adolescents and Young Adults(AsiDNA) | Phase 1 / Phase 2 | terminated | May 27, 2022 | Institut Curie | IDMC recommendations | Other (stated, no rule matched) |
| NCT03971734 | Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the… | Phase 1 | terminated | Jun 3, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated \[NCI decided to terminate ABTC Consortium due to NCI moving in different direction for… | Other (stated, no rule matched) |
| NCT04608812 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a… | Phase 1 | terminated | Oct 29, 2020 | OncoSynergy, Inc. | Slow enrollment and financial constraints. | Enrollment / accrual |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in…(PIVOT IO 020) | Phase 1 / Phase 2 | terminated | Jan 29, 2021 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based… | Phase 1 / Phase 2 | terminated | Apr 20, 2021 | Xennials Therapeutics Australia Pty Ltd | Study was terminated by IP Holder (collaborator), PinotBio Inc. | Other (stated, no rule matched) |
| NCT02885324 | Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in… | Phase 2 | terminated | Aug 31, 2016 | Indiana University | Failure to meet accrual goals. | Enrollment / accrual |
| NCT03352427 | Study of Dasatinib in Combination With Everolimus for Children and Young Adults With… | Phase 2 | terminated | Nov 24, 2017 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02607124 | A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy | Phase 1 / Phase 2 | terminated | Nov 17, 2015 | Children's Hospital Medical Center, Cincinnati | A competing trial was opened for patient population with combination of ribociclib and everolimus. | Other (stated, no rule matched) |
| NCT04220892 | Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for High Grade Glioma | Early Phase 1 | withdrawn | Jan 7, 2020 | Jose Carrillo | One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab +… | Safety / toxicity |
| NCT02598011 | A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC…(Toca7) | Phase 1 | withdrawn | Nov 5, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02500459 | Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection | Early Phase 1 | terminated | Jul 16, 2015 | Michael Vogelbaum, MD, PhD | PI Left institution | Investigator |
| NCT02305056 | Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma…(CARBONOMIC) | Phase 1 | terminated | Dec 2, 2014 | University Hospital, Grenoble | not stated | Not stated |
| NCT00003535 | Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT01902771 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | Phase 1 | terminated | Jul 18, 2013 | Edward Ziga | Lack of Accrual | Enrollment / accrual |
| NCT00469534 | Minimized Time to Beam in Patients With High Grade Gliomas | N/A | withdrawn | May 4, 2007 | Alberta Health services | not stated | Not stated |
| NCT00826930 | Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and… | Phase 1 | terminated | Jan 22, 2009 | Diffusion Pharmaceuticals Inc | Sponsor business decision, not based on safety or efficacy data. | Safety / toxicity |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | Phase 2 | terminated | Oct 24, 2007 | Methodist Healthcare - Memphis | Principal Investigator has left the institution | Investigator |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials